Mopetia (Paliperidone)

Paliperidone, the active ingredient in Mopetia, is an atypical antipsychotic presented as an intramuscular injection for intramuscular use. It is indicated for the treatment of schizophrenia and schizoaffective disorder in adult patients, helping to manage psychotic symptoms and improve functional outcomes.

GNH USA supplies Mopetia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. Our supply chain ensures product integrity from manufacturing sites in the European Union to end‑users.

Paliperidone is an atypical antipsychotic used in the management of psychotic disorders.

Schizophrenia: reduces positive and negative symptoms and helps prevent relapse. Schizoaffective disorder: stabilizes mood and psychotic symptoms, supporting functional recovery.

Paliperidone may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Akathisia: inner restlessness and urge to move. - Weight gain: increase in body weight. - Somnolence: drowsiness or sleepiness. - Increased prolactin: menstrual disturbances or galactorrhea.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever, muscle rigidity, autonomic instability. - Tardive dyskinesia: involuntary, repetitive movements, potentially irreversible. - Seizures: risk of convulsions, especially at higher doses.

Paliperidone requires careful monitoring and specific precautions.

Pregnancy: safety not established; use only if benefits outweigh risks. Breastfeeding: unknown; consider potential infant exposure. Elderly: monitor for orthostatic hypotension and increased sedation. Cardiovascular: assess for QT prolongation and hypotensive episodes. Metabolic: monitor weight, glucose, and lipid levels. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Paliperidone can interact with other medicines, necessitating vigilance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase plasma concentrations. - QT‑prolonging agents: additive risk of arrhythmia. - Alpha‑adrenergic antagonists: may enhance hypotensive effect.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may worsen cognitive side effects. - Concomitant antipsychotics: increase risk of extrapyramidal symptoms. - CNS depressants (e.g., benzodiazepines): may enhance sedation.